Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521939 | 0.76 | MAPT (0.31) | — | |
| SCHEMBL297505 | 0.74 | CYP3A4 (0.52) | GAAMAPK1 | |
| SCHEMBL11674778 | 0.72 | TLR9 (0.39) | — | |
| SCHEMBL6545361 | 0.71 | MEN1 (0.45) | — | |
| SCHEMBL8961761 | 0.70 | MAPT (0.31) | GAA | |
| SCHEMBL12076779 | 0.68 | CYP2E1 (0.44) | — | |
| SCHEMBL296899 | 0.67 | MAPK1 (0.42) | KDM4EGAAMAPK1 | |
| SCHEMBL233233 | 0.67 | HPGD (0.39) | KDM4EGAAMAPK1 | |
| SCHEMBL1586114 | 0.67 | CYP19A1 (0.31) | — | |
| SCHEMBL114701 | 0.67 | MAPK1 (0.34) | KDM4EGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738955-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2020-11-18 | — | — | EP | claimed |
| US-10287274-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-05-14 | — | — | US | claimed |
| US-10239868-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-26 | — | — | US | claimed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-8426429-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-04-23 | — | — | US | claimed |
| EP-1776350-B1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | claimed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | claimed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | claimed |
| CN-101035770-B | 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV | 2011-02-23 | — | — | CN | claimed |
| CN-101035770-A | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-12 | — | — | CN | claimed |
| US-4978664-A | Analgesic, anti-rheumatic, and anti-inflammatory agent | STERLING DRUG INC. (US) | 1990-12-18 | — | — | US | claimed |
| US-4885295-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | STERLING DRUG INC. (US) | 1989-12-05 | — | — | US | claimed |
| US-RE32761-E | ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT | STERLING DRUG INC. (US) | 1988-10-04 | — | — | US | claimed |
| CN-87108111-A | Novel imidazole derivative and preparation method thereof | — | 1988-09-28 | — | — | CN | claimed |
| EP-0270091-A1 | Imidazole derivatives, processes for the preparation of the same, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments of therapeutic value, and intermediates formed during said processes | TANABE SEIYAKU CO., LTD. (JP) | 1988-06-08 | — | — | EP | claimed |
| US-4634776-A | ANALGESIC, ANTIRHEUMATIC, ANTIINFLAMMATORY | STERLING DRUG, INC. (US) | 1987-01-06 | — | — | US | claimed |
| US-4581354-A | ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1986-04-08 | — | — | US | claimed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | claimed |
| EP-0007605-B1 | A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR | CIBA-GEIGY AG (CH) | 1982-09-15 | — | — | EP | claimed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287274-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | KDM4E 2700/4885GAA 1186/4885MAPK1 3778/4885 |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | KDM4E 3458/4885GAA 2556/4885MAPK1 3112/4885 |
| US-10239868-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | KDM4E 2700/4885GAA 1186/4885MAPK1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.